Gossamer Bio
GOSS0.20670.78% ( +0.0016 )
Gossamer Bio (GOSS)
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertensio...
- Open
- 0.2057
- High
- 0.2119
- Low
- 0.1820
- Prev. Close
- 0.2051
- Volume
- 30.26M
- Turnover
- 5.95M
- Avg Price
- 0.1966
- Bid/Ask Ratio
- --
- Amplitude
- 14.58%
- 52wk High
- 3.8700
- Volume Ratio
- 0.36
- Turnover Ratio
- 9.66%
Gossamer Bio Analyst Rating
View MoreForecast & Rating
Jul 28, 2026Price forecast
$3.861765.51%
Forecast & RatingBuy
7analysts
- Strong buy28.57%
- Buy14.29%
- Hold42.86%
- Sell0.00%
- Strong sell14.29%
News
- US Stock Market Update · 1 day ago, 04:32 PM
Gossamer Bio jumps 10% in after-hours trading as Leerink upgrades to Outperform
- US Stock Market Update · 1 day ago, 12:50 PM
Gossamer Bio climbs 2% as Leerink upgrades to Outperform
- US Stock Market Update · 1 day ago, 09:10 AM
Gossamer Bio surges over 10% as Leerink upgrades to Outperform
- benzinga_article · 1 day ago, 07:05 AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga_article · 1 day ago, 06:33 AM
This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
- rttnews · 1 day ago, 10:34 PM
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired
